SparingVision shares trial updates for rare eye disease gene therapies
Pharmaceutical Technology
SEPTEMBER 15, 2023
The company is also planning to expand its Phase I/II PRODYGY lead candidate trial in retinitis pigmentosa to three more US sites.
Fri.Sep 15, 2023
264 
FTC takes aim at pharma patent tactics used to block generics
Bio Pharma Dive
SEPTEMBER 15, 2023
The antitrust regulator is examining what it describes as abuse of the FDA “Orange Book” — another step in its scrutiny of pharma business practices.
Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cure Genetics and Frametact seek gene cures for neurological ailments
Pharmaceutical Technology
SEPTEMBER 15, 2023
Cure Genetics has entered a partnership and licensing deal with Frametact to develop gene therapy for familial neurological ailments.
J&J to phase out Janssen name in corporate rebrand
Bio Pharma Dive
SEPTEMBER 15, 2023
Janssen will be recast as Johnson & Johnson Innovative Medicine, melding the drugs division’s identity more closely with its parent.
NICE recommends Idorsia’s chronic insomnia treatment for UK patients
Pharmaceutical Technology
SEPTEMBER 15, 2023
The therapy will be available to patients who have insomnia multiple times a week, do not respond to CBTi, and whose wakeful day is severely impacted.
Advanced Therapies Europe: From bench to bedside and boardroom
Drug Discovery World
SEPTEMBER 15, 2023
Advanced Therapies Europe took place from 9-12 September 2023 in Portugal. DDW’s Megan Thomas asked attendees: What is most important to scale from discovery to commercialisation of cell and gene therapies (CGTs)? Joel Eichmann, Co-Founder, Green Elephant Biotech It always comes down to time-to-market and risk minimisation. To cover these, it is critical to choose [.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
J&J, GSK and other companies knowingly marketed ineffective decongestants, lawsuits claim
Fierce Pharma
SEPTEMBER 15, 2023
Questions first circulated about decongestant pills containing phenylephrine in 2007. | Several companies, including Johnson & Johnson, GSK, Procter & Gamble and Walgreens, face class-action lawsuits that claim the drugmakers knew that over-the-counter cold and flu pills containing phenylephrine did not work as advertised.
Charles River and Related Sciences partner for AI drug platform
Pharmaceutical Technology
SEPTEMBER 15, 2023
Charles River has signed a multi-programme collaboration agreement with Related Sciences (RS) for the AI-powered drug platform, Logica.
Astellas to invest over €330m in a new facility in Ireland
Pharma Times
SEPTEMBER 15, 2023
The site will contribute to the development and commercialisation of antibody drugs - News - PharmaTimes
EMA CHMP recommends approval for Moderna’s updated Covid-19 vaccine
Pharmaceutical Technology
SEPTEMBER 15, 2023
The EMA CHMP has recommended granting marketing authorisation for Moderna’s updated Covid-19 vaccine targetting XBB.1.5 sublineage.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
MIT’s new technique to remotely evaluate cerebral palsy patients
Pharma Times
SEPTEMBER 15, 2023
The method could also be beneficial for Parkinson’s disease and strokes - News - PharmaTimes
Remote Patient Monitoring market will reach $760m by 2030
Pharmaceutical Technology
SEPTEMBER 15, 2023
A new report found that the Remote Patient Monitoring (RPM) sector will grow, since the pandemic revealed the benefits of remote healthcare.
Gilead-backed Lyndra Therapeutics cuts nearly a quarter of staff as ph. 3 data nears
Fierce Pharma
SEPTEMBER 15, 2023
Lyndra Therapeutics is laying off roughly 23% of its staff, two months after the company swapped out longtime CEO Patricia Hurter, Ph.D., and as a pivotal trial for a long-acting, oral schizophreni | Lyndra Therapeutics is laying off staff two months after a CEO swap and as interim data from a pivotal trial for a schizophrenia drug nears. The company's lead asset is a long-acting, oral version of Johnson & Johnson's Uzedy.
Signal: Danaher’s $5.7bn acquisition of Abcam faces stand-off with founder
Pharmaceutical Technology
SEPTEMBER 15, 2023
Abcam founder Jonathan Milner has declared his intention to vote against the acquisition of the company in which he holds a large stake.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Bayer CEO plots management cuts as first step in larger overhaul: Reuters
Fierce Pharma
SEPTEMBER 15, 2023
Just a few months into Bill Anderson's tenure as Bayer's CEO, the helmsman is reportedly looking to trim the drugmaker's management ranks. | The CEO is eying some big changes, but he wants to show investors he's prepared to act swiftly, Reuters reports. The publication cited three people "familiar with the matter" in reporting the behind-the-scenes developments at Bayer.
argenx wins EMA CHMP nod for subcutaneous Vyvgart in myasthenia gravis
Pharmaceutical Technology
SEPTEMBER 15, 2023
The positive opinion relied on a comparator study that showed the subcutaneous version was non-inferior to the intravenous one.
After FDA setback, PTC Therapeutics' DMD drug Translarna faces possible market withdrawal in Europe
Fierce Pharma
SEPTEMBER 15, 2023
A “surprised and extremely disappointed” PTC Therapeutics is scrambling to keep its Duchenne muscular dystrophy therapy Translarna on the European market after a detrimental review. | A “surprised and extremely disappointed” PTC Therapeutics is scrambling to keep its Duchenne muscular dystrophy therapy Translarna on the European market after a detrimental review.
Market cap rebound by top 20 biopharmaceutical companies in Q2 2023
Pharmaceutical Technology
SEPTEMBER 15, 2023
Market capitalisation increased by a total of 2.3% from $3.49tn in Q1 2023 to $3.56tn in Q2 2023, according to GlobalData.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Bristol Myers banks on 25-plus label expansions to help weather IRA, Revlimid generics and more
Fierce Pharma
SEPTEMBER 15, 2023
With the potential for more than two dozen label expansions on the horizon, Bristol Myers Squibb bets its pipeline can help it withstand the pressure from the Inflation Reduction Act and a trio of | With the potential for more than two dozen label expansions on the horizon, Bristol Myers Squibb bets its pipeline can help it withstand the pressure from the Inflation Reduction Act and a trio of weighty patent losses.
Generate:Biomedicines secures $273m to advance therapeutic portfolio
Pharmaceutical Technology
SEPTEMBER 15, 2023
Generate:Biomedicines has secured $273m in Series C financing round to expedite its generative AI therapeutics portfolio.
FTC fires shot across pharma's bows over 'improper' patents
pharmaphorum
SEPTEMBER 15, 2023
FTC fires shot across pharma's bows over 'improper' patents Phil.
Iovance’s PDUFA date for lifileucel pushed due to FDA backlog
Pharmaceutical Technology
SEPTEMBER 15, 2023
The FDA pushed lifileucel’s PDUFA date from November this year to 24 February 2024 citing resource constraints.
Roles and Responsibilities of Specialized Clinical Supply Experts
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Pelican Appoints New CEO
Pharmaceutical Commerce
SEPTEMBER 15, 2023
Protective case manufacturer hires James Curleigh, as company prepares to further innovation and expand.
How Payers Are Reacting to Insulin Price Changes
Drug Channels
SEPTEMBER 15, 2023
Today’s guest post comes from Nicole Mayer, Senior Analyst at MMIT. Nicole summarizes MMIT’s research on payers’ views of two crucial market changes: (1) the Inflation Reduction Act of 2022’s requirement to cap insulin prices at $35 for Medicare beneficiaries, and (2) manufacturers’ reduction in list prices for certain insulin products. She also discusses MMIT’s research on such glucagon-like peptide 1 (GLP-1) drugs as Ozempic and Mounjaro.
Scientists find elusive cause of cell death in Alzheimer's
pharmaphorum
SEPTEMBER 15, 2023
Scientists find elusive cause of cell death in Alzheimer's Phil.
HP&M’s Faraz Siddiqui to Speak at Informa’s Medicaid Drug Rebate Program (MDRP) Summit 2023 on Value Based Programs
FDA Law Blog
SEPTEMBER 15, 2023
On September 18-20, Informa Connect will hold its annual #MDRPSummit in Chicago (and via livestream) to discuss the complex, ever-evolving laws and regulations in the government pricing and price reporting space. This three-day summit will feature numerous presentations, workshops and networking opportunities featuring government officials, drug pricing and reimbursement lawyers and experts and industry leaders.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Driving data & analytics transformation in life sciences
pharmaphorum
SEPTEMBER 15, 2023
Driving data & analytics transformation in life sciences Mike.
New patent for Neurocrine drug INGREZZA
Drug Patent Watch
SEPTEMBER 15, 2023
Annual Drug Patent Expirations for INGREZZA Ingrezza is a drug marketed by Neurocrine and is included in one NDA. It is available from one supplier. There are twenty patents protecting… The post New patent for Neurocrine drug INGREZZA appeared first on DrugPatentWatch - Make Better Decisions.
FDA capacity forces delay to Iovance's cell therapy
pharmaphorum
SEPTEMBER 15, 2023
FDA capacity forces delay to Iovance's cell therapy Phil.
New patent for Axsome Malta drug SUNOSI
Drug Patent Watch
SEPTEMBER 15, 2023
Annual Drug Patent Expirations for SUNOSI Sunosi is a drug marketed by Axsome Malta and is included in one NDA. It is available from two suppliers. There are thirteen patents… The post New patent for Axsome Malta drug SUNOSI appeared first on DrugPatentWatch - Make Better Decisions.
Accelerating Clinical Supply Through Integrated Drug Development
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Let's personalize your content